Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HERTHENA-Breast04: Patritumab deruxtecan vs treatment of physician's choice in HR+/HER2- unresectable or metastatic breast cancer
jRCT2031250297Phase 3Recruiting
- Sponsor
- Merck & Co.
- Start
- Dec 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 3, randomised, open-label trial of patritumab deruxtecan in breast cancer (2 arms), sponsored by Merck & Co. Primary endpoints: Progression-free survival and Overall survival. Started Dec 2025; status: recruiting.
02
Drugs
patritumab deruxtecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on jRCT2031250297.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250297.